Chronic kidney disease and mortality in fragility fracture patients: revisiting GFR thresholds

慢性肾脏病与脆性骨折患者的死亡率:重新审视肾小球滤过率阈值

阅读:2

Abstract

PURPOSE: Chronic kidney disease (CKD) is common in older adults. Still, its significance in patients with fragility fractures remains unclear, as does the clinical relevance of only mild-to-moderate CKD (GFR of 45-59 ml/min/1.73 m(2)) in older adults in general. We investigated how different eGFR categories (< 45, 45-59, and ≥ 60 ml/min/1.73 m(2)) are associated with mortality and functional outcomes in orthogeriatric patients. METHODS: This retrospective cohort study included 453 consecutive patients admitted to an orthogeriatric unit from 2015 to 2023. Estimated glomerular filtration rate (eGFR) at admission was categorized into < 45, 45-59, and ≥ 60 ml/min/1.73 m(2). Outcomes included mortality (via Kaplan-Meier curves, regression, and ROC analysis), in-hospital complications, and functional recovery. Mediation by frailty was also analyzed. RESULTS: Patients had a mean age of 82.9 ± 6.8 years; 74.8% were female. CKD was prevalent: 52.4% had eGFR < 60, and 33.6% had eGFR < 45 ml/min/1.73 m(2). Those with eGFR < 45 ml/min/1.73 m(2) had worse baseline functional status, more comorbidities, and poorer recovery. The 45-59 group showed similar or better outcomes than those with eGFR ≥ 60 ml/min/1.73 m(2), including mortality. Long-term all-cause mortality was significantly higher in the < 45 ml/min/1.73 m(2) group (HR 1.77, 95% CI 1.25-2.51), but not in the 45-59 ml/min/1.73 m(2) group (HR 1.01, 95% CI 0.64-1.58). CONCLUSION: In orthogeriatric patients, an eGFR < 45 ml/min/1.73 m(2) identifies individuals at higher risk of poor outcomes. However, eGFR 45-59 is not associated with adverse prognosis and may not warrant classification as CKD in this context. A lower diagnostic threshold may better reflect clinical realities in this population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。